news
New model could be used to predict shelf life of drugs
Researchers have developed a model that describes how antibody solutions separate into different phases and could be used to anticipate the stability and shelf-life of drugs.
List view / Grid view
MedImmune
news
FDA approves Fasenra for severe eosinophilic asthma
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...
article
Pursuing great science with MedImmune
As part of EPR’s Women in Pharma series, Dr Jane Osbourn, Vice President of Research & Development, MedImmune, talks to Science Editor Dr Zara Kassam about the importance of breaking through self-imposed barriers…
news
Imfinzi wins breakthrough therapy designation
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
news
Inducing protein aggregation by extensional flow makes drugs less effective
9 May 2017 | By University of Leeds
Data from a new device demonstrates maximal levels of extensional flow which manufacturers could use for different processes, without damaging proteins...
news
AstraZeneca’s potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation
30 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
news
MedImmune out-licenses inflammatory diseases medicine to Allergan
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is...
news
FSA grants Fast Track designation for MEDI8852
7 March 2016 | By Victoria White
MedImmune has received Fast Track designation from the FDA for MEDI8852 for the treatment of patients hospitalised with Type A strain influenza...
news
Tremelimumab mesothelioma trial fails to meet primary endpoint
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
news
Trial of IMCgp100, durvalumab and tremelimumab in melanoma starts
20 January 2016 | By Victoria White
Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma...
news
Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
news
Innate Pharma and Astrazeneca announce co-development and commercialisation collaboration for IPH2201
24 April 2015 | By Victoria White
Innate Pharma has signed a co-development and commercialisation agreement with AstraZeneca to accelerate and broaden the development of IPH2201...
news
MedImmune and Immunocore collaborate to conduct immuno-oncology combination trials in metastatic melanoma
17 April 2015 | By Victoria White
MedImmune has entered into a collaboration with Immunocore to conduct immuno-oncology combination trials in metastic melanoma...
news
MEDI8897 receives FDA Fast Track designation for the prevention of respiratory disease caused by RSV in infants
9 April 2015 | By Victoria White
MedImmune has announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for the development of MEDI8897...
news
Advaxis submits investigational new drug application for Phase 1/2 study of ADXS-HPV and Medimmune’s medi4736 for the treatment of HPV-associated cervical and head & neck cancer
14 November 2014 | By MedImmune and Advaxis
Dose confirmation safety study of ADXS-HPV and MEDI4736 combination therapy to initiate in early 2015...
